Literature DB >> 10754399

Local application of capsaicin into the draining lymph nodes attenuates expression of adjuvant-induced arthritis.

D Lorton1, C Lubahn, C Engan, J Schaller, D L Felten, D L Bellinger.   

Abstract

Adjuvant-induced experimental arthritis (AA) was examined in adult male Lewis rats after isolated capsaicin (CAPS)-induced loss of small, nonmyelinated, afferent fibers in lymph nodes draining the site of adjuvant challenge. AA was induced by intradermal injection of Freund's complete adjuvant (CFA) into the subplantar area of the right hind paw. Controls received similar injections of mineral oil, the vehicle for CFA. One day later, half of the CFA-treated rats and half of the mineral oil-treated rats received injections of CAPS bilaterally into the draining lymph nodes (DLN). The DLN of remaining rats were injected with 50:50 ethanol/sterile physiological saline, the vehicle for CAPS. This paradigm resulted in four groups designated: CFA/CAPS, CFA/vehicle, vehicle/CAPS and vehicle/vehicle. Since substance P (SP) is present in small, nonmyelinated, afferent fibers, the target of the neurotoxin, CAPS, a radioimmunoassay specific for SP was used to verify the loss of these nerve fibers. CAPS injections into the DLN resulted in a loss in SP concentration in the DLN, with no depletion of SP in the spleen or sciatic nerve. These findings support the destruction of SP-containing nerves, which we interpret as verification of the selective loss of small, non-myelinated afferent nerves in the DLN with no significant spread of the neurotoxin to the nearby sciatic nerves which supply small, nonmyelinated, afferent fibers to the hind limb joints. Also, preservation of SP content in spleen indicates CAPS did not circulate via the lymphatic drainage. No chronic inflammation was observed in the fore or hind limbs from rats treated with the vehicle for CFA (vehicle/vehicle, vehicle/CAPS) at any time during the study. In CFA/vehicle-treated rats, bilateral, symmetrical inflammation of the hind limbs was apparent 14 days after challenge with CFA, and became progressively more inflamed through day 20. In contrast, hind limb inflammation in arthritic rats treated with CAPS was not symmetrical. On days 14 and 20 after challenge with CFA, the inflammatory response in the left hind limb, contralateral to the site of CFA injection, was significantly (p < 0.05) attenuated compared with the response seen on the right side of CFA/CAPS-treated rats, and with the response seen in left hind limb of CFA/vehicle-treated animals. In fact, the mean dorsoplantar width of contralateral hind limbs from CFA/CAPS-treated animals was not different from that measured in non-AA control groups. These findings support a role for small, nonmyelinated, sensory nerves that modulate immune responses in DLN in the development and progression of AA in Lewis rats. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10754399     DOI: 10.1159/000026429

Source DB:  PubMed          Journal:  Neuroimmunomodulation        ISSN: 1021-7401            Impact factor:   2.492


  12 in total

Review 1.  Without nerves, immunology remains incomplete -in vivo veritas.

Authors:  Andrew J Shepherd; James E G Downing; Jaleel A Miyan
Journal:  Immunology       Date:  2005-10       Impact factor: 7.397

Review 2.  Dietary factors in rheumatic autoimmune diseases: a recipe for therapy?

Authors:  Shani Dahan; Yahel Segal; Yehuda Shoenfeld
Journal:  Nat Rev Rheumatol       Date:  2017-04-13       Impact factor: 20.543

Review 3.  Role of peripheral nerve fibres in acute and chronic inflammation in arthritis.

Authors:  Georg Pongratz; Rainer H Straub
Journal:  Nat Rev Rheumatol       Date:  2012-11-13       Impact factor: 20.543

4.  Role of Mast Cells and C-Sensory Fibers in Concanavalin A-Induced Paw Edema in Two Rat Strains.

Authors:  Stanislava Stanojević; Nataša Kuštrimović; Katarina Mitić; Vesna Vujić; Mirjana Dimitrijević
Journal:  Inflammation       Date:  2015-08       Impact factor: 4.092

5.  After-effects of consecutive sessions of transcranial direct current stimulation (tDCS) in a rat model of chronic inflammation.

Authors:  Gabriela Laste; Wolnei Caumo; Lauren Naomi Spezia Adachi; Joanna Ripoll Rozisky; Isabel Cristina de Macedo; Paulo Ricardo Marques Filho; Wania Aparecida Partata; Felipe Fregni; Iraci L S Torres
Journal:  Exp Brain Res       Date:  2012-07-03       Impact factor: 1.972

6.  Amphiphilic Poly-N-vinylpyrrolidone Nanoparticles as Carriers for Nonsteroidal, Anti-Inflammatory Drugs: Pharmacokinetic, Anti-Inflammatory, and Ulcerogenic Activity Study.

Authors:  Andrey Kuskov; Dragana Nikitovic; Aikaterini Berdiaki; Mikhail Shtilman; Aristidis Tsatsakis
Journal:  Pharmaceutics       Date:  2022-04-24       Impact factor: 6.525

7.  Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.

Authors:  T Bisogno; L Hanus; L De Petrocellis; S Tchilibon; D E Ponde; I Brandi; A S Moriello; J B Davis; R Mechoulam; V Di Marzo
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

8.  Effects of indomethacin-loaded nanocapsules in experimental models of inflammation in rats.

Authors:  A Bernardi; A C C V Zilberstein; E Jäger; M M Campos; F B Morrone; J B Calixto; A R Pohlmann; S S Guterres; A M O Battastini
Journal:  Br J Pharmacol       Date:  2009-05-06       Impact factor: 8.739

9.  Contribution of α,β-Amyrenone to the Anti-Inflammatory and Antihypersensitivity Effects of Aleurites moluccana (L.) Willd.

Authors:  Nara Lins Meira Quintão; Lilian W Rocha; Gislaine Franciele Silva; Simone Reichert; Vanessa D Claudino; Ruth Meri Lucinda-Silva; Angela Malheiros; Márcia Maria De Souza; Valdir Cechinel Filho; Tania M Bellé Bresolin; Marina da Silva Machado; Theodoro Marcel Wagner; Christiane Meyre-Silva
Journal:  Biomed Res Int       Date:  2014-10-19       Impact factor: 3.411

10.  Herbal compounds and toxins modulating TRP channels.

Authors:  Joris Vriens; Bernd Nilius; Rudi Vennekens
Journal:  Curr Neuropharmacol       Date:  2008-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.